It is noteworthy that TIMP2 IGFBP7 has been approved by the US Food and Drug Administration as an aid in the risk assessment for moderate or severe (stage 2–3) acute kidney injury within the next 12 h. The gene discussed is IGFBP7; the disease is acute kidney injury.